Drugs / Denikitug
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05007782 | Aug 2021 → Dec 2028 expected | neoplasm | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07546812 | Aug 2026 → Jan 2030 expected | Her2-receptor negative breast cancer, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07527858 | May 2026 → Dec 2028 expected | colorectal cancer | Gilead Sciences | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Denikitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07546812 ↗ |
| Known as | DEN | “study drug, Denikitug (DEN, GS-1811)” NCT07546812 ↗ |
| Modality | Monoclonal antibody | “an Afucosylated Anti-CCR8 Monoclonal Antibody” NCT05007782 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT05007782 ↗ |
| Target | CCR8 | “Anti-CCR8” NCT05007782 ↗ |